Immunomedics Inc. executives are avoiding drawing any connection between good manufacturing practice issues raised in a pre-license site inspection report of the firm’s Morris Plains, New Jersey, facility and the chemistry, manufacturing and controls issues raised in the agency’s complete response to the firm’s biologics license application for a breakthrough cancer therapy.
The US FDA granted the firm’s sacituzumab govitecan breakthrough therapy status for a narrow indication – third-line or greater treatment of patients with metastatic triple-negative breast cancer – and the antibody-drug conjugate has huge potential in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?